Agenus (FRA:AJ8) Institutional Ownership : 22.57% (As of May. 24, 2024)

View and export this data going back to . Start your Free Trial

What is Agenus Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Agenus's institutional ownership is 22.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Agenus's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Agenus's Float Percentage Of Total Shares Outstanding is 99.18%.

Agenus Institutional Ownership Historical Data

The historical data trend for Agenus's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Institutional Ownership Chart

Agenus Historical Data

The historical data trend for Agenus can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	29.10	28.07	28.71	26.53	26.90	23.58	23.60	23.22	22.45	22.57

Agenus Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Agenus (FRA:AJ8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

AGEN:USA AJ81:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines